RxDoctor Payments Data

Gregory Bratton, MD

Family Medicine · Millsap, TXNPI 1861657355

Payments from drug & device makers

$26,050in general payments, 2019–2025

Across 877 payments — averaging $29.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$14K
  • Henry Schein, Inc.$2K
  • AstraZeneca$1K
  • Novo Nordisk$953
  • Amgen$796
  • Lilly USA, LLC$717
  • plus $6K from 54 others

What the payments were for

  • Speaking & faculty fees$12,12547%
  • Travel & lodging$2911%
  • Food & beverage$13,60352%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)255$13,906
Henry Schein, Inc.1$1,500
AstraZeneca57$1,441
Novo Nordisk85$953
Amgen(2 entities)49$796
Lilly USA, LLC51$717
Boehringer Ingelheim26$492
Corium, LLC26$414
Pfizer21$332
GSK16$253
Almatica Pharma LLC12$249
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)17$240
Otsuka America Pharmaceutical, Inc.12$216
Supernus Pharmaceuticals, Inc.13$213
Merck13$201
Abbott10$200
Bayer11$193
Amarin Pharma, Inc.13$187
Hydrocision, Inc.2$173
Corcept Therapeutics7$163
Takeda Pharmaceuticals U.S.A., Inc.9$155
Si-bone, Inc.2$147
Kowa Pharmaceuticals America, Inc.9$144
Exact Sciences8$141
Sumitomo Pharma America, Inc.6$121
Verona Pharma, Inc.5$113
Mylan Specialty L.p.7$110
Johnson & Johnson(3 entities)6$107
Scilex Pharmaceuticals Inc.5$107
Novartis5$97
Astellas Pharma US Inc5$86
Nevro Corp.4$83
Biohaven Pharmaceuticals, Inc.5$81
Adlon Therapeutics L.p.5$80
Antares Pharma, Inc.4$79
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$77
Esperion Therapeutics, Inc.5$69
Eisai Inc.3$69
Pacira Therapeutics, Inc.4$64
Phathom Pharmaceuticals, Inc.6$62
Teva Pharmaceuticals USA, Inc.4$62
Verity Pharmaceuticals Inc.3$59
Tolmar, Inc.4$59
Sanofi-aventis U.S. LLC3$59
Jazz Pharmaceuticals Inc.3$57
IBSA Pharma Inc.4$56
Radius Health, Inc.2$54
Clarus Therapeutics Inc.4$54
Ironshore Pharmaceuticals Inc.3$51
Inspire Medical Systems, Inc.1$45
Axsome Therapeutics, Inc.3$45
Dexcom, Inc.2$41
Idorsia Pharmaceuticals US Inc2$40
Boston Scientific2$38
Nabriva Therapeutics, PLC3$37
Shire North American Group Inc3$34
Valeritas, Inc.2$33
Lundbeck LLC2$32
Nestle Healthcare Nutrition Inc.2$32
Globus Medical2$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,050 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$343,644
Medicare patients
747
Services billed
10,818

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin187$219,884
OzempicSemaglutide216$218,808
EliquisApixaban157$168,857
TrulicityDulaglutide101$154,398
FarxigaDapagliflozin Propanediol128$131,336
Trelegy ElliptaFluticasone/Umeclidin/Vilanter103$120,725
RybelsusSemaglutide66$118,742
MounjaroTirzepatide82$102,263
ProliaDenosumab40$69,459
VascepaIcosapent Ethyl54$45,339
TymlosAbaloparatide17$43,697
LinzessLinaclotide43$41,802
Tresiba Flextouch U-200Insulin Degludec27$40,157
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog40$36,661
XareltoRivaroxaban30$34,574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$953$337,551282 claims
Lilly USA, LLCTrulicity, Mounjaro$717$256,660183 claims
Boehringer IngelheimJardiance, Glyxambi$492$233,247200 claims
PfizerEliquis, Premarin, Nurtec Odt$332$199,970216 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,441$160,878167 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$253$137,192132 claims
AmgenProlia$796$69,45940 claims
MerckJanuvia, Janumet, Belsomra$201$55,78846 claims
Radius Health, Inc.Tymlos$54$43,69717 claims
AbbVieLinzess$13,906$41,80243 claims
Johnson & JohnsonXarelto$107$34,57430 claims
Otsuka America Pharmaceutical, Inc.Rexulti$216$28,11319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Millsap

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →